Deutsche Bank Starts Regeneron Pharma (REGN) at Buy; Antibody Collaboration is Underappreciated

Deutsche Bank initiates coverage on Regeneron Pharma (NASDAQ: REGN) with a Buy.

Deutsche analyst says, "We see Regeneron as having two key core assets: 1) VEGF Trap-Eye that is being developed with Bayer for age-related macular degeneration (AMD), and 2) an antibody development program with Sanofi-Aventis. We believe the Street is underestimating the cash flow these two businesses will bring in over the next 5 years. We are initiating coverage of REGN with a BUY based on our expectation that VEGF Trap-Eye will take 15% global share and bring in $2B+, and the antibody platform will generate $4B by 2025E (25% probability-adjusted)."

For more ratings news on Regeneron Pharma click here and for the rating history of Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $42.85 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Regeneron Pharma (REGN) PT Raised to $756 at Bernstein SocGen Group
• JPMorgan Downgrades JD Logistics Inc (2618:HK) (JDLGF) to Neutral
• Evercore ISI Starts Alvotech SA (ALVO) at Outperform